Weighed Down by 13% in One Month, Ipsen Stock Declines Further Following Jefferies Downgrade
The Parisian biopharmaceutical laboratory resumes its downward trend in a declining Paris market. A London research firm has recently hardened its view, at a time when the stock is trading below all of its moving averages.
Jefferies Downgrades to Underperform and Lowers Price Target to 130 Euros
The Ipsen share fell 1.86% to 142.30 € during the session, in the lower part of the SBF 120, as the index declined 0.77%. Jefferies published today an analyst rating at "underperform", with a price target reduced from 135 € to 130 €. This target is 8.6% below the current price.
The stock has lost 13.1% over one month and 15.5% over three months. It had plunged more than 7% on September 22, following U.S. authorization of a generic version of lanreotide, the active ingredient in Somatuline, produced by Amneal. This competitor's arrival is among the risks cited by the company during its H1 2026 results publication on July 30.
Stock Price Below Its Three Moving Averages, 1.3 € Away from the 140.50 € Support Level
The price is below the 20-day MA (deviation of -4.45%), the 50-day MA (-9.14%) and the 200-day MA (-7.84%). The 140.50 € support level is less than 1.3% away from the current price: it had been breached on October 5 during the session before being recovered. The RSI at 40 shows neither overbought nor oversold conditions.
During the H1 2026 results publication on July 30, Ipsen had raised its financial targets for the fiscal year and highlighted the positive Phase III results of Dysport in migraine. Based on expected earnings per share, the stock is trading at approximately 9.4 times the earnings of the current fiscal year, according to the consensus of surveyed analysts. The 140.50 € level remains the closest technical reference point.
